Kisspeptin-10 vs PT-141
Head-to-head comparison of Kisspeptin-10 (Metastin 45-54 (KiSS-1 Fragment)) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Kisspeptin-10 | PT-141 |
|---|---|---|
| Category | Performance | Performance |
| Full Name | Metastin 45-54 (KiSS-1 Fragment) | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 1,302.41 Da | 1,025.2 Da |
| Half-Life | ~4 minutes | ~2.7 hours |
| Amino Acids | 10 | 7 |
| Typical Dose | 100-500 mcg | 1.75 mg |
| Route | SC / IV | SC |
| Purity | — | — |
| Studies Count | 156 | 178 |
| Research Status | Clinical Trials | FDA Approved |
Kisspeptin-10 Benefits
- ✓Stimulates natural testosterone production
- ✓Activates GnRH release
- ✓Increases LH and FSH
- ✓Does not suppress HPG axis
- ✓May restore fertility
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
Kisspeptin-10 Dosing
Standard: 100-500 mcg SC daily|Hormone Optimization: 200 mcg SC twice daily|PCT Support: 300 mcg SC daily for 2-4 weeks|Research typically uses IV infusion in clinical settings
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
Kisspeptin-10 Side Effects
- ⚠Common (Mild): Injection site discomfort, mild flushing
- ⚠Rare: Temporary mood changes, headache
- ⚠Well tolerated in clinical studies
- ⚠Does not cause HPG axis suppression
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
Kisspeptin-10
Kisspeptin-10 has growing clinical evidence. Multiple human studies demonstrate reliable GnRH stimulation and subsequent testosterone increase. Being actively studied for reproductive medicine, including IVF protocols and hypogonadism. Unique advantage of not suppressing the HPG axis.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.